PromoCell GmbH, a leading global manufacturer of primary human cells and specialized cell culture media for biomedical research, announces its entry into the Good Manufacturing Practice (GMP) field. At the 32nd ESGCT Congress in Seville, Spain, PromoCell will showcase its Custom GMP Cell Culture Media Services tailored for clinical applications and further manufacturing in the cell-based therapy industry. PromoCell’s Custom GMP Cell Culture Media Services bridge the gap between research and clinical application, offering Excipient GMP-grade¹ cell culture media manufacturing and expert guidance through the entire research-to commercialization journey.

“We noticed an increasing demand for advanced cell culture media in regenerative medicine and cell-based therapy, and we are thrilled to introduce our GMP cell culture medium service portfolio to the life science community at the ESGCT Congress,” says Dr. Irma Börcsök, CEO of PromoCell. “This launch is a testament to our dedication to supporting customers with our long-standing cell culture medium expertise every step of the way, from discovery to preclinical, clinical, and commercial manufacturing. With both off-the-shelf and customized Excipient GMP-grade solutions now available, we’re delivering service-driven offerings that meet high regulatory standards, empowering scientists to scale their innovations with confidence and compliance.”

“This launch marks a major milestone for our team,” adds Dr. Lucía Cespón, GMP Business Unit Lead at PromoCell. “We’ve worked closely with our clients in clinical applications to ensure that both our Custom GMP Cell Culture Media Services and our advanced cell culture media product portfolio ‘PromoExQ’ ensure the precision, flexibility, and compliance that modern translational research demands.”